Guilford Pharmaceuticals Inc. and Gliatech Inc. have entered into a definitive merger agreement pursuant to which Guilford will acquire all of the outstanding common stock of Gliatech. The transaction combines the capabilities of both companies in biopolymer development and the development of novel drugs for the treatment of central nervous system disorders. The combined company Read more about Guilford And Gliatech To Merge[…]